| Followers | 18 |
| Posts | 8575 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Monday, January 26, 2026 7:15:02 AM
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
January 26, 2026 12:00 PM
ACCESS Newswire
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to report its fourth quarter 2025 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
Original: Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
Recent MRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:24:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:21:25 PM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Moderna Resolves Global Patent Litigation with Arbutus/Genevant • ACCESS Newswire • 03/03/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:04:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 02:56:47 PM
- European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 02/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:49:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 03:26:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/20/2026 09:03:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2026 09:02:04 PM
- Moderna to Present at Upcoming Conferences in March 2026 • ACCESS Newswire • 02/19/2026 12:00:00 PM
- Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission • ACCESS Newswire • 02/18/2026 12:00:00 PM
- Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE • ACCESS Newswire • 02/17/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:41:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 12:02:14 PM
- Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates • ACCESS Newswire • 02/13/2026 12:00:00 PM
- Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 • ACCESS Newswire • 02/10/2026 11:00:00 PM
- Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico • ACCESS Newswire • 02/10/2026 12:00:00 PM
- The $71 Billion Cancer Shift: Why The FDA Is Speeding Up • GlobeNewswire Inc. • 02/05/2026 02:26:03 PM
- Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. • GlobeNewswire Inc. • 02/04/2026 02:15:00 PM
- Dr. David Berman to Join Moderna as Chief Development Officer • ACCESS Newswire • 01/30/2026 12:30:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
